Ganymed Robotics brings in additional than $21M in Sequence B funding

Take heed to this text

Ganymed’s surgical system can be utilized for whole knee arthoplasty (TKA) procedures. | Supply: Ganymed Robotics

Ganymed Robotics, an organization growing laptop imaginative and prescient software program and robotics applied sciences for orthopedic surgical procedures, introduced that it raised greater than $21.3 million (€21 million) in an oversubscribed Sequence B spherical. 

The corporate’s expertise platform acts as a co-manipulated robotic assistant for whole knee arthroplasty (TKA), often known as a knee substitute. The table-mounted robotic has a multimodal sensor embedded in its arm. The sensor fuels a proprietary algorithmic suite that permits the robotic to register the affected person’s anatomy with out making any contact. 

Cathay Well being, a world multi-stage €500 million fund that invests in firm whose expertise allows advances in medication, led the funding spherical. Credit score Mutuel Innovation, Kurma Companions, BNP Paribas Développement and internationally famend surgeons additionally participated within the spherical.

“The help of this high-profile group of traders, specialised in innovation and healthcare is a robust endorsement of the work completed and of our imaginative and prescient for the way forward for orthopedic surgical procedure. We’re desirous to enter this new part of progress,” Sophie Cahen, co-founder and CEO of Ganymed Robotics, stated. “With our distinctive robot-with-eyes platform, we’re dedicated to offering all surgeons and care facilities, massive and small, with an easy-to-use and cost-effective resolution that may radically enhance affected person final result, surgeon expertise and general effectivity of joint substitute interventions.”

Ganymed Robotics plans to make use of the funding to help its growth into France and the US, finalize the commercial improvement of its surgical system, speed up regulatory and advertising and marketing improvement throughout geographies and diversify its innovation product pipeline. 

“We have now been impressed by Ganymed’s next-generation expertise. We’re trying ahead to working alongside such a gifted crew and contribute to creating orthopedic surgical procedure safer, extra accessible, extra surgeon-centric and finally extra environment friendly for all,” Dr. Steve Oesterle, former SVP Medication and Expertise at Medtronic, now Enterprise Associate at Cathay Well being, stated.

Since beginning in 2018, the corporate has made nice strides in the direction of bringing its surgical system to market. It has efficiently accomplished prototype checks, initiated industrialization of its first system dedication to TKA via strategic partnership with producers and secured a strong patent portfolio. 

Ganymed’s mission is to enhance affected person final result, surgeon expertise and the general effectivity of care with its expertise. It’s primarily based in Paris, and hopes to proceed to develop its technological capabilities to different orthopedic surgical procedures.